Mechanism of Action.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification that improves stability. It binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. This preserves the natural GH feedback axis, unlike exogenous GH administration. The resulting GH elevation drives IGF-1 production in the liver, which mediates downstream effects on lipolysis, particularly in visceral adipose depots. Tesamorelin selectively targets visceral fat while largely preserving subcutaneous fat and lean mass.
Research Summary.
The clinical evidence for tesamorelin is robust. In Phase III trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 26 weeks compared to placebo. The PARADIGM study demonstrated sustained visceral fat reduction over 52 weeks with continued treatment. Beyond its FDA-approved indication, research has explored tesamorelin for age-related visceral adiposity, metabolic syndrome markers, and cognitive health. A notable 2019 study in the Annals of Neurology found that tesamorelin improved cognitive function in older adults, likely through IGF-1-mediated neuroprotective pathways. It also improved triglyceride levels and markers of hepatic steatosis in clinical trials.
Side Effects & Safety.
Tesamorelin has a well-characterized safety profile from extensive clinical trials. Common side effects include injection site reactions (erythema, pruritus, pain), arthralgia, peripheral edema, and myalgia. It increases IGF-1 levels, which requires monitoring given theoretical concerns about long-term elevated IGF-1 and cell proliferation. Contraindicated in patients with active malignancy, hypothalamic-pituitary disruption, and pregnancy. Glucose metabolism effects are generally modest, though fasting glucose should be monitored in pre-diabetic individuals.
Legal Status & Access.
Tesamorelin is an FDA-approved prescription medication marketed as Egrifta SV. It is legally available through standard prescription channels for HIV-associated lipodystrophy. Off-label use for body composition and cognitive health requires physician prescribing. Research-grade tesamorelin is available from peptide suppliers for in-vitro research. Tesamorelin is not a controlled substance but does require a prescription for human clinical use.